Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a pre-menopausal female 20 to 49 years of age.~* Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound assessed by a central reader and verification that a fibroid present met the following criteria:~  * At least 1 fibroid with diameter ≥ 2 cm (longest diameter), or multiple small fibroids with a total uterine volume of ≥ 200 cm³ to ≤ 2,500 cm³ (approximately 22 weeks' gestation) as documented by a centrally read ultrasound.~ * Only intramural, submucosal non-pedunculated, and subserosal fibroids qualified subjects for enrollment (intracavitary pedunculated fibroids were exclusionary).~ * Ultrasound procedures were performed during the Screening Period, and subjects were not randomized until the investigator reviewed the central reader results verifying the inclusion requirements.~* Subject has a history of regular menstrual cycles between 24 to 35 days.~* Subject has heavy uterine bleeding associated with uterine fibroids as evidenced by blood loss \> 80 mL during 2 screening menstrual cycles, measured by the alkaline hematin method.~Exclusion Criteria:~* Subject has had a myomectomy, uterine artery embolization, or high intensity focused ultrasound for fibroid destruction within 1 year prior to randomization or any history of endometrial ablation.~* Subject has a history of osteoporosis or other metabolic bone disease.~* Subject shows evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including depression), or neurologic diseases or any uncontrolled medical illness such as uncontrolled type 2 diabetes.~* Subject has a history of clinically significant condition(s) including but not limited to:~  * Endometriosis~ * Epilepsy or seizures~ * Type 1 diabetes~ * Any cancer (except basal cell carcinoma of the skin), including breast or ovarian cancer or subject has taken any systemic cancer chemotherapy

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 4 Elagolix 400 mg QD (Type: EXPERIMENTAL): Participants received elagolix 400 mg once a day (QD) for 3 months.
- Cohort 4 Elagolix 100 mg BID (Type: EXPERIMENTAL): Participants received elagolix 100 mg twice a day (BID) for 3 months.
- Cohort 4 Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to elagolix BID for 3 months.
- Cohort 1 Elagolix 200 mg BID (Type: EXPERIMENTAL): Participants received elagolix 200 mg twice a day for 3 months.
- Cohort 1 Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to elagolix twice a day for 3 months.
- Cohort 3 Elagolix 200 mg BID + LD E2/NETA (Type: PLACEBO_COMPARATOR): Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.
- Cohort 5 Elagolix 600 mg QD (Type: EXPERIMENTAL): Participants received elagolix 600 mg once a day for 3 months.
- Cohort 2 Elagolix 300 mg BID (Type: EXPERIMENTAL): Participants received elagolix 300 mg twice a day for 3 months.
- Cohort 2 Placebo (Type: EXPERIMENTAL): Participants received placebo to elagolix BID for 3 months.
- Cohort 6 Elagolix 300 mg BID + CEP (Type: EXPERIMENTAL): Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).